Autifony Therapeutics announces positive results from Phase I study of AUT00206, a first-in-class Kv3 modulator for treatment of schizophrenia

Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous system, today announced positive findings from a Phase Ia clinical trial of AUT00206, a first-in-class Kv3 modulator in development for the treatment of schizophrenia, as well as the start of the first of two Phase Ib studies with the molecule.